美股异动 | 肺炎球菌疫苗达后期临床试验目标 Vaxcyte(PCVX.US)高开超50%

智通财经
Oct 05
【美股异动 | 肺炎球菌疫苗达后期临床试验目标 Vaxcyte(PCVX.US)高开超50% 】智通财经APP获悉,周一,Vaxcyte(PCVX.US)跳空高开超50%,截至发稿,涨幅约53%,市值128亿美元。消息面上,该公司的肺炎球菌疫苗达到后期临床试验目标,根据公司评估,VAX-31——一种处于研究阶段的31价肺炎球菌结合疫苗——的关键性III期OPUS-1试验取得了积极的顶线结果。该试验评估了该候选疫苗在成人中的安全性、耐受性及免疫原性,以预防侵袭性肺炎球菌病和肺炎球菌性肺炎。在OPUS-1试验中,VAX-31在50岁及以上受试者中达到了所有预先设定的共同主要免疫原性终点。这些试验结果将为即将向美国食品药品监督管理局提交的生物制品许可申请奠定基础。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10